1,325 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Sargent Investment Group LLC

Sargent Investment Group LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,325 shares of the company’s stock, valued at approximately $896,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the third quarter worth about $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories in the fourth quarter worth about $29,000. WealthCollab LLC acquired a new position in IDEXX Laboratories in the second quarter worth about $30,000. Caitong International Asset Management Co. Ltd acquired a new position in IDEXX Laboratories in the third quarter worth about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $560.88 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market cap of $44.24 billion, a P/E ratio of 41.30, a P/E/G ratio of 3.07 and a beta of 1.56. The business’s fifty day moving average is $563.06 and its two-hundred day moving average is $626.82. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on IDXX shares. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. UBS Group dropped their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.